


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
DATA OF PHASE II CLINICAL STUDY OF KRAS G12C INHIBITOR
“GARSORASIB TABLET (D-1553)”
WILL BE PRESENTED AT 2024 AACR

The board of directors (the “**Board**”) of the Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announced that the latest results of phase II clinical study (NCT05383898) of KRAS G12C Inhibitor “Garsorasib Tablet (D-1553)”, which is jointly developed by the Group, will be presented at the Annual Meeting 2024 of American Association for Cancer Research (“**AACR**”), for the treatment of patient with non-small cell lung cancer (“**NSCLC**”) with KRAS G12C mutation.

Details of report:

No.: CT246

Title of abstract: Open-label, single-arm, multicenter, phase 2 trial of garsorasib in KRAS G12C-mutated non-small-cell lung cancer

About Garsorasib:

Garsorasib is a novel, potent KRAS G12C inhibitor that selectively and irreversibly binds to KRAS G12C mutant proteins and inactivates them for the treatment of a wide range of cancers, including NSCLC and colorectal cancers with KRAS G12C mutations.

In June 2022, Garsorasib was granted Breakthrough Therapy designation by the Center for Drug Evaluation (“**CDE**”) of the National Medical Products Administration of China. In January 2024, the marketing application of Garsorasib was filed to and accepted by the CDE for the treatment of locally advanced or metastatic NSCLC with disease progression following or intolerant to prior first-line systemic therapy and with confirmed KRAS G12C mutation.

At present, Garsorasib is undergoing international multi-center clinical studies in the first-line treatment of NSCLC and other solid tumors such as colorectal cancer, and some of the study results have been presented at influential international academic conference platforms, which have demonstrated the good safety and anti-tumor activity of Garsorasib.

In August 2023, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (“**Chia Tai Tianqing**”), a subsidiary of the Company, entered into an exclusive license and cooperation agreement with InventisBio Co. Ltd. (“**InventisBio**”). Chia Tai Tianqing was granted an exclusive license by InventisBio to develop, register, manufacture and commercialise Garsorasib in Mainland China. Meanwhile, based on potential future data sharing cooperation, Chia Tai Tianqing will be granted a certain proportion of rights outside of Mainland China in due course.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 13 March 2024

As at the date of this announcement, the Board of the Company comprises seven executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.